Literature DB >> 18000218

Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene.

Qingguo Tao1, Junya Fujimoto, Taoyan Men, Xiaofeng Ye, Jiong Deng, Ludovic Lacroix, John L Clifford, Li Mao, Carolyn S Van Pelt, J Jack Lee, Dafna Lotan, Reuben Lotan.   

Abstract

BACKGROUND: Lung cancers develop via multiple genetic and epigenetic changes, including inactivation of tumor suppressor genes. We previously cloned human G protein-coupled receptor family C type 5A (GPRC5A), whose expression is suppressed in some human lung carcinoma cells, and its mouse homolog Gprc5a.
METHODS: We generated Gprc5a knockout mice by homologous recombination and studied their phenotype by macroscopic observation and microscopic histologic analysis of embryos and lungs of 1- to 2-year-old mice. GPRC5A mRNA expression was analyzed by reverse transcription-polymerase chain reaction in surgical specimens of 18 human lung tumors and adjacent normal tissues and by analyzing previously published data from 186 lung tumor tissues of a variety of histologic types and 17 normal lung samples. Human embryonic kidney, human non-small-cell lung cancer, and mouse lung adenocarcinoma cells were transfected with a GPRC5A expression vector or a control vector, and colony formation in semisolid medium was assayed. Statistical tests were two-sided.
RESULTS: Homozygous knockout mice developed many more lung tumors at 1-2 years of age (incidence: 76% adenomas and 17% adenocarcinomas) than heterozygous (11% adenomas) or wild-type (10% adenomas) mice. Human GPRC5A mRNA levels were lower in most (11 of 18 [61%]) human lung tumors than in adjacent normal tissues. The mean GPRC5A mRNA level in adenocarcinoma (n = 139), squamous cell carcinoma (n = 21), small-cell lung cancer (n = 6), and carcinoid (n = 20) tissues was 46.2% (P = .014), 7.5% (P<.001), 5.3% (P<.001), and 1.8% (P<.001), respectively, that in normal lung tissues (n = 17) GPRC5A transfection suppressed colony formation in semisolid medium of immortalized human embryonic kidney, human non-small-cell lung cancer, and mouse lung adenocarcinoma cells by 91%, 91%, and 68%, respectively, compared with vector controls (all P<.001).
CONCLUSIONS: Gprc5a functions as a tumor suppressor in mouse lung, and human GPRC5A may share this property. The Gprc5a-deficient mouse is a novel model to study lung carcinogenesis and chemoprevention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18000218     DOI: 10.1093/jnci/djm208

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  50 in total

1.  Knockout of the tumor suppressor gene Gprc5a in mice leads to NF-kappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis.

Authors:  Jiong Deng; Junya Fujimoto; Xiao-Feng Ye; Tao-Yan Men; Carolyn S Van Pelt; Yu-Long Chen; Xiao-Feng Lin; Humam Kadara; Qingguo Tao; Dafna Lotan; Reuben Lotan
Journal:  Cancer Prev Res (Phila)       Date:  2010-03-30

2.  RAI3 is overexpressed in gastric adenocarcinoma but unrelated to prognosis.

Authors:  Nathaniel Melling; Kai Bachmann; Maximillian Bockhorn; Oliver Mann; Jakob Robert Izbicki; Katharina Grupp
Journal:  Int J Clin Exp Pathol       Date:  2019-02-01

3.  A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas.

Authors:  Humam Kadara; Junya Fujimoto; Taoyan Men; Xiaofeng Ye; Dafna Lotan; Ju-Seog Lee; Reuben Lotan
Journal:  Neoplasia       Date:  2010-06       Impact factor: 5.715

4.  Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a.

Authors:  Junya Fujimoto; Sayuri Nunomura-Nakamura; Yihua Liu; Wenhua Lang; Tina McDowell; Yasminka Jakubek; Dalia Ezzeddine; Joshua Kapere Ochieng; Jason Petersen; Gareth Davies; Junya Fukuoka; Ignacio I Wistuba; Erik Ehli; Jerry Fowler; Paul Scheet; Humam Kadara
Journal:  Int J Cancer       Date:  2017-07-17       Impact factor: 7.396

5.  Gprc5a-deficiency confers susceptibility to endotoxin-induced acute lung injury via NF-κB pathway.

Authors:  Yueling Liao; Hongyong Song; Dongliang Xu; Huike Jiao; Feng Yao; Jingyi Liu; Yadi Wu; Shuangshuang Zhong; Huijing Yin; Shuli Liu; Xiaofei Wang; Wenzheng Guo; Beibei Sun; Baohui Han; Y Eugene Chin; Jiong Deng
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  Comparative functional genomics analysis of NNK tobacco-carcinogen induced lung adenocarcinoma development in Gprc5a-knockout mice.

Authors:  Junya Fujimoto; Humam Kadara; Taoyan Men; Carolyn van Pelt; Dafna Lotan; Reuben Lotan
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

7.  G-protein coupled receptor family C, group 5, member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small-cell lung cancer.

Authors:  Junya Fujimoto; Humam Kadara; Melinda M Garcia; Mohamed Kabbout; Carmen Behrens; Diane D Liu; J Jack Lee; Luisa M Solis; Edward S Kim; Neda Kalhor; Cesar Moran; Amir Sharafkhaneh; Reuben Lotan; Ignacio I Wistuba
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

8.  GPRC5A overexpression predicted advanced biological behaviors and poor prognosis in patients with gastric cancer.

Authors:  Honggen Liu; Yunchao Zhang; Xuwen Hao; Fanming Kong; Xiaojiang Li; Jianchun Yu; Yingjie Jia
Journal:  Tumour Biol       Date:  2015-07-31

9.  Genome-Wide Gene Expression Changes in the Normal-Appearing Airway during the Evolution of Smoking-Associated Lung Adenocarcinoma.

Authors:  Jacob Kantrowitz; Ansam Sinjab; Li Xu; Tina L McDowell; Smruthy Sivakumar; Wenhua Lang; Sayuri Nunomura-Nakamura; Junya Fukuoka; Georges Nemer; Nadine Darwiche; Hassan Chami; Arafat Tfayli; Ignacio I Wistuba; Paul Scheet; Junya Fujimoto; Avrum E Spira; Humam Kadara
Journal:  Cancer Prev Res (Phila)       Date:  2018-01-30

10.  Identifying the localization and exploring a functional role for Gprc5c in the kidney.

Authors:  Premraj Rajkumar; Boyoung Cha; Jianyi Yin; Lois J Arend; Teodor G Păunescu; Yoshio Hirabayashi; Mark Donowitz; Jennifer L Pluznick
Journal:  FASEB J       Date:  2018-01-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.